Medicines optimisation · September 2026
Medicines optimisation projects for ICBs and PCNs
We place clinical pharmacists on defined medicines projects: best value DOAC reviews, price-per-unit and ghost generic work, lipid optimisation, cardiovascular risk (CVD), and the work in your ICB’s prescribing incentive scheme. Here is where every ICB in England stands, from NHSBSA’s prescribing data.
England in September 2026
- Price-per-unit savings
- £16,152,394in one month, across 1,299 PCNs
- DOAC prescriptions that were best value
- 83%generic apixaban or rivaroxaban tablets
- Other DOACs, cost per prescription
- £43.89against £1.98 for best value
- Ghost generics
- £1,142,297at 2,305 practices, part of the price-per-unit savings
Your ICB
Compare all 36 ICBs
Ordered by price-per-unit savings for every 1,000 registered patients, most first.
Source: NHSBSA English Prescribing Dataset, September 2026, Open Government Licence v3.0. How we work these out is below.
Project work
Get a delivery plan for your ICB
You know the data. The hard part is the time to do the work, practice by practice. Tell us the project and we’ll send a plan:
- which practices to start with, and why
- the work your prescribing scheme already pays practices for
- how many pharmacist sessions it needs
Then we place clinical pharmacists to do it, for as long as the project needs.
How we work these out
Every figure is one month, September 2026, from NHSBSA’s English Prescribing Dataset for GP practices, as the data gives it: no saving is estimated or scaled up to a year.
- Price-per-unit savings are what each practice would have saved if it had paid what the cheapest tenth of practices in England paid per unit for the same medicine, counted where the practice would save at least £10 on that medicine in the month. This is OpenPrescribing’s price-per-unit method. Some savings can’t be made, for example where a medicine is short or on price concession.
- Ghost generics are generic medicines prescribed as one maker’s product instead of by their generic name, where England mostly prescribes the generic. They are part of the price-per-unit savings, not extra to them.
- Best value DOACs are generic apixaban and generic rivaroxaban tablets, NHS England’s joint best value direct-acting oral anticoagulants. We show the cost per prescription of each group, not a saving: changing anyone’s anticoagulant is a clinical decision made with the patient after a review.
Sources
- English Prescribing Dataset (NHSBSA), September 2026: items, quantities and cost by practice and medicine
- Commissioning recommendations for national procurement for DOACs (NHS England): which DOACs are best value
- OpenPrescribing (Bennett Institute, University of Oxford): the price-per-unit method
Contains public sector information licensed under the Open Government Licence v3.0.